2024 Market Overview According to MIX Online (24年国内医療用薬市場 11兆5000億円突破で最高額を更新 ワクチン大幅伸長 1000億円超に８製品 | ニュース | ミクスOnline) published by AnswersNews as of March/05/2025, Japan’s domestic prescription drug market grew by 2.0% year-on-year in 2024, reaching a record-high of ¥11.5 trillion. This marks the second consecutive year of record-breaking growth. The expansion was driven mainly by a substantial increase in vaccine […]
Overview of New Drug ApprovalsAccording to the report (2024年 国内新薬承認取得数ランキング…最多は11承認のアストラゼネカ、新規有効成分はファイザーがトップ | AnswersNews) published by AnswersNews on Feb/25/2025, a total of 56 companies received approval for new pharmaceuticals in Japan in 2024, an increase of seven from the previous year. In total, 148 new drugs were approved, including 66 new active ingredients and 82 other approvals. […]
Introduction to Astellas’ Pioneering Regulatory Submission According to the news (News | Astellas Pharma Inc.) released by Astellas Pharma on Feb/05/2025, they have submitted a manufacturing and marketing approval application in Japan for avacincaptad pegol (ACP), branded as IZERVAY, targeting geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Notably, this application is under Japan’s […]
Overview of Japan’s Pharmaceutical Market in 2024 According to the news (【2024年国内医薬品売上高トップ10】キイトルーダ、1851億円で首位…2位にリクシアナ、「共連れ」のオプジーボは3位 | AnswersNews) released by AnswersNews on 01/27/2025, In 2024, MSD’s immune checkpoint inhibitor, Keytruda, led Japan’s pharmaceutical market with sales reaching ¥185.1 billion. Following closely, Daiichi Sankyo’s anticoagulant, Lixiana, secured the second position with ¥147.7 billion in sales, slightly surpassing Ono Pharmaceutical’s Opdivo, […]
Japanese Pharmaceutical and Medical Device Act revisions aim to establish a pharmaceutical industry that ensures stable and reliable access to medicines for the public.